Our previous studies demonstrated that MRMI of EDB-FN with MT218 is effective in detecting multiple aggressive cancers, including PDAC, and in monitoring tumor response to anticancer therapies in preclinical models 33, 48, 56, based on the role of EDB-FN in cancer EMT and invasion. This evidence concerns the gene FN1 and cancer.